PDCD1 and hepatocellular carcinoma: Immune checkpoint inhibitors (ICIs), particularly antibodies targeting programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1), have exhibited promising potential at improving tumor response and survival of HCC patients.